Translational Sciences Section, Jonsson Comprehensive Cancer Center, School of Nursing, University of California, Los Angeles, Los Angeles, CA, United States of America.
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.
PLoS One. 2019 Jun 27;14(6):e0218917. doi: 10.1371/journal.pone.0218917. eCollection 2019.
The role of insulin resistance (IR) in developing postmenopausal breast cancer has not been thoroughly resolved and may be confounded by lifestyle factors such as obesity. We examined whether genetically determined IR is causally associated with breast cancer risk.
We conducted Mendelian randomization (MR) analyses using individual-level data from our previous meta-analysis of a genome-wide association study (GWAS) (n = 11,109 non-Hispanic white postmenopausal women). Four single-nucleotide polymorphisms were associated with fasting glucose (FG), 2 with fasting insulin (FI), and 6 with homeostatic model assessment-IR (HOMA-IR) but were not associated with obesity. We used this GWAS to employ hazard ratios (HRs) for breast cancer risk by adjusting for potential confounding factors.
No direct association was observed between comprising 12 IR genetic instruments and breast cancer risk (HR = 0.93, 95% CI: 0.76-1.14). In phenotype-specific analysis, genetically elevated FG was associated with reduced risk for breast cancer (main contributor of this MR-effect estimate: G6PC2 rs13431652; HR = 0.59, 95% CI: 0.35-0.99). Genetically driven FI and HOMA-IR were not significantly associated. Stratification analyses by body mass index, exercise, and dietary fat intake with combined phenotypes showed that genetically elevated IR was associated with greater breast cancer risk in overall obesity and inactive subgroups (single contributor: MTRR/LOC729506 rs13188458; HR = 2.21, 95% CI: 1.03-4.75).
We found complex evidence for causal association between IR and risk of breast cancer, which may support the potential value of intervention trials to lower IR and reduce breast cancer risk.
胰岛素抵抗(IR)在绝经后乳腺癌发展中的作用尚未得到彻底解决,并且可能与肥胖等生活方式因素混淆。我们研究了遗传决定的 IR 是否与乳腺癌风险有因果关系。
我们使用来自我们之前的全基因组关联研究(GWAS)荟萃分析的个体水平数据进行孟德尔随机化(MR)分析(n = 11109 名非西班牙裔白人绝经后妇女)。有四个单核苷酸多态性与空腹血糖(FG)相关,两个与空腹胰岛素(FI)相关,六个与稳态模型评估胰岛素抵抗(HOMA-IR)相关,但与肥胖无关。我们利用这项 GWAS,通过调整潜在的混杂因素,使用乳腺癌风险的危害比(HR)。
没有观察到 12 个 IR 遗传工具与乳腺癌风险之间存在直接关联(HR = 0.93,95%CI:0.76-1.14)。在表型特异性分析中,遗传上升高的 FG 与乳腺癌风险降低相关(此 MR 效应估计的主要贡献者:G6PC2 rs13431652;HR = 0.59,95%CI:0.35-0.99)。遗传驱动的 FI 和 HOMA-IR 与乳腺癌风险无显著相关性。按体重指数、运动和饮食脂肪摄入量进行分层分析,结果表明,在总体肥胖和不活跃亚组中,遗传上升高的 IR 与更大的乳腺癌风险相关(单一贡献者:MTRR/LOC729506 rs13188458;HR = 2.21,95%CI:1.03-4.75)。
我们发现了 IR 与乳腺癌风险之间存在因果关系的复杂证据,这可能支持降低 IR 和降低乳腺癌风险的干预试验的潜在价值。